SMPD3 and metabolic disease: Similarly, statins, fatty acid synthase (FASN) inhibitors, and neutral sphingomyelinase 2 (nSMase2) inhibitors—primarily used for treating cancer or metabolic diseases [174,175,176]—are receiving significant attention for their potential to inhibit viral release by altering membrane lipid composition, though their clinical application as antiviral therapies requires further validation.